Results 171 to 180 of about 5,933,393 (275)

Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA [PDF]

, 2016
Natella Rakhmanina, Kam S Lam, Jaclyn Hern, Heather A. Young, Alex Walters, Amanda D. Castel   +5 more
openalex   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Advance Care Planning Interventions for Adults With Chronic Kidney Disease: A Systematic Review. [PDF]

J Ren Care
Tiansaard J, Bloomer MJ, Purtell L, Bonner A.   +3 more
europepmc   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Research Code Sharing in Support of Gold Standard Science. [PDF]

J Diabetes Sci Technol
Klonoff DC, Espinoza J, Mader JK, Heinemann L, Cobelli C, Kerr D, Kovatchev B, Najafi B, Prahalad P, Zheng Y, Shao MM, Scheideman AF, DuNova AY, Kohn M, Umpierrez GE, Wong TY, Abdel Malek A, Agus MSD, Ahn DT, AlSaad R, Al-Sofiani ME, Armstrong D, Arnold MA, Bee YM, Bequette BW, Bellazzi R, Cengiz E, Chase JG, Chen H, Chen JY, Cichosz SL, Cinar A, Clements MA, Close KL, Cuadros J, Contreras I, Datta G, Dhatariya K, Doyle FJ, Drincic A, Facchinetti A, Fleming GA, Foreman J, Gabbay MAL, Gutierrez-Osuna R, Healey E, Hoang TD, Jacobs PG, Kulzer B, La Belle J, Lee AY, Lee CS, Lee WA, Liepmann D, Maahs D, Mathioudakis N, Meo SA, Metwally AA, Misra S, Mohan V, Moon SJ, Raeder H, Rhee C, Rhee EJ, Scheinker D, Shah VN, Sheng B, Snyder MP, Sode K, Spanakis EK, Svensson J, Vaswani N, Vareth M, Vehi J, Wallia A, Waki K, Wang T, Williams E, Wolf RM, Wong JC, Yeshiwas S, Zilbermint M, Shah SN.   +82 more
europepmc   +1 more source

A review of natural remedies commonly used by Ethiopian immigrants in the USA [PDF]

, 2017
Bisrat Hailemeskel, Fekadu Fullas, Anteneh Habte, Ranyia Ali Al Matari, D.T. Brewer   +4 more
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Publisher Correction: Landscape fire emissions from the 5th version of the Global Fire Emissions Database (GFED5). [PDF]

Sci Data
van der Werf GR, Randerson JT, van Wees D, Chen Y, Giglio L, Hall J, Vernooij R, Mu M, Binte Shahid S, Barsanti KC, Yokelson R, Morton DC.   +11 more
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Comparative Blood-Based Transcriptomic Profiles of Prostate Cancer Patients from South Africa and the USA: A Cross-Sectional Pilot Study. [PDF]

J Cancer
Koduru SV, Kidd M, Pieters A, Nagel SE, Millar RP, Halim AB.   +5 more
europepmc   +1 more source